The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer

BACKGROUND: Substantial evidence supports the use of inexpensive β-AR antagonists (beta blockers) against a variety of cancers, and the β-AR antagonist propranolol was recently approved by the European Medicines Agency for the treatment of soft tissue sarcomas. Prospective and retrospective data pub...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Biomed J
Egile Nagusiak: Montoya, Alexa, Varela-Ramirez, Armando, Dickerson, Erin, Pasquier, Eddy, Torabi, Alireza, Aguilera, Renato, Nahleh, Zeina, Bryan, Brad
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Chang Gung University 2019
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717753/
https://ncbi.nlm.nih.gov/pubmed/31466709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bj.2019.02.003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak